Beacon Biosignals Raises $11M, Extends Series B Funding to Over $97M

Team S · 2026-04-06T14:13:56.000Z

Boston-based neurotechnology company Beacon Biosignals has raised an additional $11 million, bringing its total Series B funding to over $97 million, as it continues to expand its AI-driven brain health platform. The company is focused on building advanced AI-powered neurodiagnostic solutions, leveraging large-scale brain data to improve the understanding, diagnosis, and treatment of neurological and psychiatric conditions. Its platform combines FDA-cleared wearable EEG technology with machine learning to capture and analyze real-world brain activity at scale. Beacon’s system collects brain signals during sleep and wake cycles, generating high-quality datasets that power its proprietary AI models. These models are designed to identify early disease signatures and predict treatment responses, addressing a major gap in precision medicine for brain health. The company’s technology is already being used by leading biopharmaceutical companies and research organizations, supporting drug development programs and enabling more accurate clinical endpoints in neuroscience. With the extended funding, Beacon Biosignals plans to scale its data platform, accelerate neurobiomarker discovery, and expand clinical adoption, further strengthening its position in the growing intersection of AI and neurotechnology. The funding reflects increasing investor interest in AI-driven healthcare and precision neuroscience, as the industry seeks more objective, data-driven approaches to understanding complex brain disorders.

Member Login Get Access

Beacon Biosignals Raises $11M, Extends Series B Funding to Over $97M | Newnex